Lupin Limited, one of India’s premier global pharmaceutical companies, announced its unaudited consolidated and standalone financial results for the first quarter ended June 30, 2026 (Q1 FY27), following its Board of Directors meeting on Thursday, August 6, 2026.

The Mumbai-headquartered pharmaceutical major posted a strong financial performance, exceeding market forecasts across revenue and profitability parameters. On a consolidated basis, total revenue from operations surged 32.04% year-on-year (YoY) to ₹82,768.9 million, compared to ₹62,683.4 million reported in the corresponding period of the previous fiscal year (Q1 FY26). On a sequential basis, operational revenue grew 10.73% over the ₹74,746.6 million achieved in Q4 FY26.

Consolidated Net Profit After Tax (PAT) for Q1 FY27 rose to ₹14,169.8 million, marking a 16.01% YoY increase over ₹12,214.6 million in Q1 FY26. Net profit attributable to the owners of the company stood at ₹14,150.0 million, resulting in Basic Earnings Per Share (EPS) of ₹30.95 for the quarter.

The quarter’s momentum was driven by steady execution across core generic formulation markets in North America and India, along with initial contributions from newly integrated international assets, including European ophthalmology specialist VISUfarma B.V.

                       LUPIN LIMITED Q1 FY27 SNAPSHOT
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ Consolidated Operational Revenue : ₹82,768.9 Million (+32.04% YoY)      │
 │ Consolidated Net Profit (PAT)    : ₹14,169.8 Million (+16.01% YoY)      │
 │ Standalone Operational Revenue   : ₹71,719.0 Million (+25.63% YoY)      │
 │ Standalone Net Profit (PAT)      : ₹27,146.0 Million (+27.56% YoY)      │
 │ Consolidated Basic EPS (Q1 FY27) : ₹30.95 per share                     │
 └─────────────────────────────────────────────────────────────────────────┘

FINANCIAL HIGHLIGHTS & COMPARATIVE TABLES

Financial Highlights Table (Consolidated)

Quarterly Performance Summary (Consolidated)

 CONSOLIDATED REVENUE & PROFIT TRAJECTORY (₹ IN MILLIONS)
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ Q1 FY26 : Revenue ₹62,683.4  │ PAT ₹12,214.6                           │
 │ Q2 FY26 : Revenue ₹66,720.0* │ PAT ₹13,100.0*                          │
 │ Q3 FY26 : Revenue ₹75,430.0* │ PAT ₹13,550.0*                          │
 │ Q4 FY26 : Revenue ₹74,746.6  │ PAT ₹14,686.7                           │
 │ Q1 FY27 : Revenue ₹82,768.9  │ PAT ₹14,169.8                           │
 └─────────────────────────────────────────────────────────────────────────┘
 *Note: Q2 and Q3 figures reflect historical interim trends.

Segment Information Table (Consolidated)

Lupin primarily operates in the Pharmaceuticals business segment, with non-pharmaceutical activities categorized under Others.

Margin Analysis Table

Balance Sheet & Financial Position Highlights

*Note: Figures estimated based on comprehensive income additions during the interim period.

Key Financial Ratios Table

BUSINESS ANALYSIS & COMPANY PROFILE

Company Overview & Global Infrastructure

Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin Limited has grown into one of the world’s largest generic pharmaceutical companies. The company holds strong market positions across key markets:

                          GLOBAL GEOGRAPHIC FOOTPRINT
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ North America : Generics, Inhalation, Complex Injectables, Biosimilars │
 │ India         : Branded Formulations (Cardiology, Respiratory, CNS)    │
 │ Europe (GmbH) : Specialized Formulations & VISUfarma Ophthalmology     │
 │ Emerging Mkts : Latin America (Mexico, Brazil) & South Africa          │
 │ API Vertical  : LMSL Active Pharmaceutical Ingredients Integration    │
 └─────────────────────────────────────────────────────────────────────────┘

• North America: Leading player in generic formulations, respiratory inhalation products, complex injectables, and biosimilars.

• India Formulations: Top 5 player in the Indian Pharmaceutical Market (IPM), with leadership in chronic therapies including cardiology, respiratory, diabetology, and central nervous system (CNS) conditions.

• Europe & Rest of World: Strong market presence in Germany (Hormosan Pharma GmbH), the UK, and Australia, expanded through the Q1 FY27 acquisition of VISUfarma B.V., an established European ophthalmic specialty company.

• Emerging Markets: Strategic operations across South Africa (Pharma Dynamics), Brazil (Medquimica), Mexico (Laboratorios Grin), and the Philippines (Multicare).

• API Business: Integrated manufacturing carried out via Lupin Manufacturing Solutions Limited (LMSL).

Strategic Competitive Strengths

1. Inhalation & Complex Generics Leadership: Expertise in respiratory solutions, backed by commercialized dry-powder inhalers (DPI) and metered-dose inhalers (MDI).

2. Backward Integration: Self-reliance in Active Pharmaceutical Ingredients (APIs) for key commercial formulations provides cost advantages.

3. Global Regulatory Compliance: Manufacturing footprint accredited by regulatory agencies including the USFDA, UK MHRA, WHO, and EMA.

DETAILED FINANCIAL ANALYSIS

Revenue Breakdown & Top-Line Performance

Lupin’s consolidated revenue from operations reached ₹82,768.9 million in Q1 FY27, up 32.04% YoY. Revenue from the sale of goods rose 33.32% YoY to ₹82,172.3 million.

 Q1 FY27 EXPENSE BREAKDOWN AS % OF TOTAL REVENUE
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ Material & Stock Purchases : 25.30%                                    │
 │ Employee Expenses          : 16.71%                                    │
 │ Depreciation & Amort.      : 5.47%                                     │
 │ Other Operating Expenses   : 28.29%                                    │
 │ Profit Before Tax Margin   : 24.37%                                    │
 └─────────────────────────────────────────────────────────────────────────┘

The top-line growth was supported by:

• Sustained demand for complex generic formulations in North America.

• Steady double-digit volume growth in the India Branded Formulations business.

• Inorganic consolidation of VISUfarma B.V. from April 1, 2026, which added ₹53,604.3 million in gross revenue across European subsidiaries (before inter-company eliminations).

Expenditure Structure & Cost Analysis

Total consolidated expenses for Q1 FY27 increased 29.56% YoY to ₹63,898.3 million, expanding at a slower pace than top-line revenue (+32.04%).

• Material Costs & Purchases: Raw material costs, stock-in-trade purchases, and inventory changes totaled ₹20,892.4 million, representing 25.24% of operational revenue compared to 28.27% in Q1 FY26. This improvement expanded gross margins by 257 bps to 74.52%.

• Employee Expenses: Employee benefits expense rose 27.70% YoY to ₹13,830.0 million, driven by workforce additions from European acquisitions and annual compensation adjustments.

• Depreciation & Amortization: Depreciation and amortization charges increased 51.46% YoY to ₹4,528.5 million, reflecting the amortization of acquired intangible assets from VISUfarma (provisionally valued at ₹15,971.1 million).

GEOGRAPHIC & SEGMENT PERFORMANCE

             GEOGRAPHIC REVENUE DISTRIBUTION TRENDS (Q1 FY27)
   ┌─────────────────────────────────────────────────────────────────┐
   │ North America Formulations  ██████████████████ 36% Share        │
   │ India Branded Formulations  ███████████████ 30% Share           │
   │ Europe & Rest of World      ██████████ 20% Share                │
   │ Emerging Markets            ██████ 8% Share                     │
   │ API & Other Businesses      ████ 6% Share                       │
   └─────────────────────────────────────────────────────────────────┘

1. North America Business

North America remains Lupin’s largest regional market, contributing approximately 36% of global sales.

• Growth Drivers: Growth was supported by volume market share gains in core generic formulations, stable pricing in the US oral solid generics portfolio, and sales momentum in complex injectables like generic Diazepam and Sugammadex injections.

• Inhalation Portfolio: Tiotropium bromide inhalation powder maintained its commercial position in the US respiratory market.

• Pipeline Progress: The company continues to advance its Abbreviated New Drug Application (ANDA) filings, targeting complex ophthalmic, injectable, and respiratory submissions.

2. India Formulations Business

The domestic branded formulations business contributed nearly 30% of global revenues.

• Therapy Focus: Lupin maintained its strong market position across chronic categories, including cardiology, anti-diabetes, respiratory, and gastroenterology.

• Consumer Healthcare: LupinLife Consumer Healthcare Limited expanded its Over-The-Counter (OTC) wellness portfolio.

• Diagnostics Network: Lupin Diagnostics Limited expanded its laboratory and sample collection footprint across Tier-1 and Tier-2 Indian cities.

3. Europe & Rest of World (RoW) Markets

• VISUfarma Integration: Effective April 1, 2026, Lupin completed the acquisition of Netherlands-based VISUfarma B.V. for a total consideration of €192.8 million (₹20,902.7 million) through its subsidiary Nanomi B.V. This transaction added an established European ophthalmic commercial infrastructure across Italy, Spain, the UK, and France.

• German Operations: Hormosan Pharma GmbH maintained steady dispatches of CNS and pain management products in Germany.

4. Emerging Markets & API Business

• Latin America: Laboratorios Grin (Mexico) and Medquimica (Brazil) recorded stable local-currency growth.

• API Vertical: Active Pharmaceutical Ingredient (API) sales through Lupin Manufacturing Solutions Limited (LMSL) provided supply chain integration for internal formulation needs while generating third-party sales.

MANAGEMENT COMMENTARY & GUIDANCE SUMMARY

Executive leadership emphasized operational execution, compliance management, and strategic capital allocation during the Q1 FY27 earnings review.

Speaking on the quarterly performance, Nilesh Gupta, Managing Director, Lupin Limited, noted:

“We have commenced FY27 on a strong note with broad-based operational growth across our core markets in North America, India, and Europe. Our focus on complex generics, respiratory solutions, and complex injectables continues to yield positive results. The strategic acquisition and integration of VISUfarma significantly enhances our commercial presence in European ophthalmology. We remain committed to maintaining strict regulatory compliance across all manufacturing locations while driving sustainable, profitable growth.”

Management Disclosures & Strategic Focus Areas

• Formal Guidance Policy: Management has not issued formal quantitative numerical revenue or margin guidance for FY27, focusing instead on qualitative execution targets.

• R&D Allocation: R&D spending is expected to remain around 7.5%–8.5% of operational revenue, directed primarily toward complex ANDA filings, biosimilars, and respiratory platforms.

• Compliance Progress: The company continues to work closely with the USFDA to maintain regulatory compliance across its global manufacturing footprint.

SWOT ANALYSIS

RISK ANALYSIS

1. Regulatory Compliance Risks: Operations remain subject to USFDA inspections. Any adverse inspection outcomes or warning letters at key manufacturing facilities could delay product launches.

2. US Generic Price Erosion: Accelerated competition in the US market could compress pricing and margins for key generic offerings.

3. Litigation & Settlement Costs: As disclosed in Note 6 to the financial statements, Lupin carries provisions related to ongoing antitrust litigation (In Re Generic Pharmaceuticals Antitrust Litigation). In April 2026, subsidiary Lupin Pharmaceuticals Inc. settled one dispute for $30.0 million (₹2,654.1 million) without admission of wrongdoing.

4. Integration of Overseas Acquisitions: Achieving planned synergies from the €192.8 million acquisition of VISUfarma B.V. requires effective commercial integration across European markets.

5. Foreign Currency Volatility: Operations in Mexico, Brazil, South Africa, and Europe expose financial statements to foreign exchange fluctuations.

VALUATION ANALYSIS & PEER COMPARISON

Lupin trades at a trailing price-to-earnings (P/E) multiple of approximately 19.5x and an EV/EBITDA multiple of 13.8x, placing its valuation in line with major Indian pharmaceutical peers.

                  P/E VALUATION COMPARISON (TTM)
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ Lupin Limited          : █ 19.5x P/E                                    │
 │ Sun Pharma             : ████ 34.2x P/E                                 │
 │ Dr. Reddy's Lab        : ██ 21.5x P/E                                   │
 │ Cipla                  : ███ 26.8x P/E                                  │
 │ Aurobindo Pharma       : █ 18.2x P/E                                    │
 │ Zydus Lifesciences     : ██ 22.1x P/E                                   │
 │ Torrent Pharma         : █████ 38.5x P/E                                │
 └─────────────────────────────────────────────────────────────────────────┘

Peer Comparison Table

INVESTMENT THESIS

Bull Case

• Complex Pipeline Launches: Continued scaling of generic injectables and inhalation products drives gross margin expansion.

• Domestic Market Growth: Chronic therapy focus enables double-digit outperformance in the Indian market.

• European Synergies: Successful integration of VISUfarma builds a high-margin European specialty ophthalmic franchise.

Bear Case

• Regulatory Delays: Inspection observations at key facilities could hold up ANDA approvals.

• US Price Erosion: Renewed generic pricing pressure could impact North American revenues.

• Tax Rate Normalization: Higher corporate tax charges could limit bottom-line growth.

                           INVESTOR MATRIX
 ┌─────────────────────────────────────────────────────────────────────────┐
 │ Ideal For   : Long-term healthcare investors seeking complex generic   │
 │               and chronic market exposure.                              │
 │ Exercise    : Investors highly sensitive to regulatory news or USFDA   │
 │ Caution       inspection updates.                                       │
 └─────────────────────────────────────────────────────────────────────────┘

FUTURE GROWTH CATALYSTS

1. Complex Injectable Launches: Expansion of the US injectable portfolio following approvals for products like Diazepam and Sugammadex injections.

2. Ophthalmology Expansion: Commercial scaling of VISUfarma’s specialty ophthalmic product suite across major European markets.

3. Biosimilar Progress: Advancement of the global biosimilar pipeline, including Ranibizumab and Pegfilgrastim.

4. Domestic Chronic Care Growth: Sustained volume expansion across core Indian cardiology, diabetology, and respiratory brands.

5. OTC & Diagnostics Scaling: Commercial expansion of consumer healthcare via LupinLife and diagnostic test volumes via Lupin Diagnostics.